Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.

Giorgino F, Yu M, Haupt A, Milicevic Z, García-Pérez LE.

Diabetes Obes Metab. 2019 Nov;21(11):2570-2575. doi: 10.1111/dom.13844. Epub 2019 Aug 16.

2.

Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.

Frias JP, Wynne AG, Matyjaszek-Matuszek B, Bartaskova D, Cox DA, Woodward B, Li YG, Tham LS, Milicevic Z.

Diabetes Obes Metab. 2019 Sep;21(9):2048-2057. doi: 10.1111/dom.13764. Epub 2019 Jun 3.

PMID:
31050143
3.

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.

Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A.

Lancet. 2018 Nov 17;392(10160):2180-2193. doi: 10.1016/S0140-6736(18)32260-8. Epub 2018 Oct 4.

PMID:
30293770
4.

Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials".

Leslie RD, Pozzilli P, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC.

Diabetes Obes Metab. 2018 Sep;20(9):2319-2320. doi: 10.1111/dom.13366. Epub 2018 Jun 10. No abstract available.

PMID:
29781106
5.

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.

Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, García-Pérez LE, Woodward DB, Milicevic Z.

Lancet Diabetes Endocrinol. 2018 May;6(5):370-381. doi: 10.1016/S2213-8587(18)30023-8. Epub 2018 Feb 23. Erratum in: Lancet Diabetes Endocrinol. 2018 Jun;6(6):e5.

PMID:
29483060
6.

Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.

Pozzilli P, Leslie RD, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC.

Diabetes Obes Metab. 2018 Jun;20(6):1490-1498. doi: 10.1111/dom.13237. Epub 2018 Feb 21.

PMID:
29377522
7.

Lipopolysaccharide induces tumor necrosis factor receptor-1 independent relocation of lymphocytes from the red pulp of the mouse spleen.

Lalić IM, Bichele R, Repar A, Despotović SZ, Petričević S, Laan M, Peterson P, Westermann J, Milićević Ž, Mirkov I, Milićević NM.

Ann Anat. 2018 Mar;216:125-134. doi: 10.1016/j.aanat.2017.12.002. Epub 2017 Dec 28.

PMID:
29289711
8.

Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).

Yu M, Brunt KV, Milicevic Z, Varnado O, Boye KS.

Clin Ther. 2017 Nov;39(11):2284-2295. doi: 10.1016/j.clinthera.2017.10.002. Epub 2017 Oct 27.

PMID:
29110972
9.

Suppression of methionine-induced colon injury of young rats by cysteine and N-acetyl-L-cysteine.

Stojanović M, Šćepanović L, Todorović D, Mitrović D, Šćepanović V, Šćepanović R, Ilić S, Šćepanović T, Borović ML, Milićević Ž, Dragutinović V, Borozan S, Lalić I, Despotović S, Djuric D.

Mol Cell Biochem. 2018 Mar;440(1-2):53-64. doi: 10.1007/s11010-017-3155-1. Epub 2017 Aug 17.

PMID:
28819915
10.

Remodeling of extracellular matrix of the lamina propria in the uninvolved human rectal mucosa 10 and 20 cm away from the malignant tumor.

Despotović SZ, Milićević NM, Milošević DP, Despotović N, Erceg P, Svorcan P, Schumacher U, Ullrich S, Mihajlović G, Kalem D, Marković S, Lalić IM, Krmpot AJ, Rabasović MD, Pantelić DV, Jovanić SZ, Rösch T, Milićević Ž.

Tumour Biol. 2017 Jul;39(7):1010428317711654. doi: 10.1177/1010428317711654.

PMID:
28718368
11.

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).

Pozzilli P, Norwood P, Jódar E, Davies MJ, Ivanyi T, Jiang H, Woodward DB, Milicevic Z.

Diabetes Obes Metab. 2017 Jul;19(7):1024-1031. doi: 10.1111/dom.12937. Epub 2017 Apr 10.

PMID:
28294499
12.

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.

Nauck MA, Frossard JL, Barkin JS, Anglin G, Hensley IE, Harper KD, Milicevic Z.

Diabetes Care. 2017 May;40(5):647-654. doi: 10.2337/dc16-0984. Epub 2017 Mar 10.

PMID:
28283565
13.

Growth of Murine Splenic Tissue Is Suppressed by Lymphotoxin β-Receptor Signaling (LTβR) Originating from Splenic and Non-Splenic Tissues.

Milićević NM, Nohroudi K, Schmidt F, Schmidt H, Ringer C, Sorensen GL, Milićević Ž, Westermann J.

PLoS One. 2016 Dec 9;11(12):e0166901. doi: 10.1371/journal.pone.0166901. eCollection 2016.

14.

Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus.

Milicevic Z.

Clin Ther. 2016 Oct 6;38(10S):e1. doi: 10.1016/j.clinthera.2016.07.013. No abstract available.

PMID:
27673601
15.

Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.

Jendle J, Testa MA, Martin S, Jiang H, Milicevic Z.

Diabetes Obes Metab. 2016 Oct;18(10):999-1005. doi: 10.1111/dom.12705. Epub 2016 Jul 22.

PMID:
27279266
16.

Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.

Mari A, Del Prato S, Ludvik B, Milicevic Z, de la Peña A, Shurzinske L, Karanikas CA, Pechtner V.

Diabetes Obes Metab. 2016 Aug;18(8):834-9. doi: 10.1111/dom.12671. Epub 2016 May 16.

PMID:
27059816
17.

The role of microfibrillar-associated protein 4 (MFAP4) in the formation and function of splenic compartments during embryonic and adult life.

Milićević NM, Schmidt F, Kunz N, Kalies K, Milićević Ž, Schlosser A, Holmskov U, Sorensen GL, Westermann J.

Cell Tissue Res. 2016 Jul;365(1):135-45. doi: 10.1007/s00441-016-2374-1. Epub 2016 Feb 22.

PMID:
26899386
18.

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.

Milicevic Z, Anglin G, Harper K, Konrad RJ, Skrivanek Z, Glaesner W, Karanikas CA, Mace K.

Diabetes Obes Metab. 2016 May;18(5):533-6. doi: 10.1111/dom.12640. Epub 2016 Mar 4.

PMID:
26847401
19.

Factors Associated With Cardiovascular Events in Patients With Type 2 Diabetes and Acute Myocardial Infarction.

Strojek K, Raz I, Jermendy G, Gitt AK, Liu R, Zhang Q, Jacober SJ, Milicevic Z.

J Clin Endocrinol Metab. 2016 Jan;101(1):243-53. doi: 10.1210/jc.2015-1962. Epub 2015 Nov 23.

PMID:
26595100
20.

Complementary Molecular Dynamics and X-ray Reflectivity Study of an Imidazolium-Based Ionic Liquid at a Neutral Sapphire Interface.

Brkljača Z, Klimczak M, Miličević Z, Weisser M, Taccardi N, Wasserscheid P, Smith DM, Magerl A, Smith AS.

J Phys Chem Lett. 2015 Feb 5;6(3):549-55. doi: 10.1021/jz5024493. Epub 2015 Jan 26.

PMID:
26261977
21.

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.

Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z.

Lancet. 2015 May 23;385(9982):2057-66. doi: 10.1016/S0140-6736(15)60936-9.

PMID:
26009229
22.

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.

Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z.

Diabetes Obes Metab. 2015 Sep;17(9):849-58. doi: 10.1111/dom.12479. Epub 2015 May 20.

23.

Erratum: efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-2158.

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z.

Diabetes Care. 2015 Mar;38(3):538. doi: 10.2337/dc15-er03. No abstract available.

24.

Establishing conditions for simulating hydrophobic solutes in electric fields by molecular dynamics: effects of the long-range van der Waals treatment on the apparent particle mobility.

Miličević Z, Marrink SJ, Smith AS, Smith DM.

J Mol Model. 2014 Aug;20(8):2359. doi: 10.1007/s00894-014-2359-5. Epub 2014 Aug 8.

PMID:
25102936
25.

Aberrant tissue positioning of metallophilic macrophages in the thymus of XCL1-deficient mice.

Milićević NM, Lalić IM, Despotović SZ, Ćirić DN, Westermann J, De Waal Malefyt R, Milićević Ž.

Anat Rec (Hoboken). 2014 Aug;297(8):1472-7. doi: 10.1002/ar.22935. Epub 2014 Apr 29.

26.

Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).

Skrivanek Z, Gaydos BL, Chien JY, Geiger MJ, Heathman MA, Berry S, Anderson JH, Forst T, Milicevic Z, Berry D.

Diabetes Obes Metab. 2014 Aug;16(8):748-56. doi: 10.1111/dom.12305. Epub 2014 May 22.

27.

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z.

Diabetes Care. 2014 Aug;37(8):2149-58. doi: 10.2337/dc13-2761. Epub 2014 Apr 17. Erratum in: Diabetes Care. 2015 Mar;38(3):538.

28.

Identification of p53 and its isoforms in human breast carcinoma cells.

Milićević Z, Bajić V, Živković L, Kasapović J, Andjelković U, Spremo-Potparević B.

ScientificWorldJournal. 2014 Jan 5;2014:618698. doi: 10.1155/2014/618698. eCollection 2014.

29.

Mutant p53 protein expression and antioxidant status deficiency in breast cancer.

Milicevic Z, Kasapovic J, Gavrilovic L, Milovanovic Z, Bajic V, Spremo-Potparevic B.

EXCLI J. 2014 Jun 23;13:691-708. eCollection 2014.

30.

P2RY12 gene polymorphisms and effect of clopidogrel on platelet aggregation.

Galić E, Vrbanić L, Kapitanović S, Catela Ivković T, Petro D, Vuković I, Bsharat RS, Milicević Z, Vcev A, Mirat J.

Coll Antropol. 2013 Jun;37(2):491-8.

PMID:
23940995
31.

Morphometric study of uninvolved rectal mucosa 10 cm and 20 cm away from the malignant tumor.

Despotović SZ, Milićević NM, Milosević DP, Despotović N, Erceg P, Bojić B, Bojić D, Svorcan P, Mihajlović G, Dorđević J, Lalić IM, Milićević Z.

Histol Histopathol. 2014 Feb;29(2):229-34. doi: 10.14670/HH-29.229. Epub 2013 Jul 17.

PMID:
23860949
32.

DNA damage in Alzheimer disease lymphocytes and its relation to premature centromere division.

Zivković L, Spremo-Potparević B, Siedlak SL, Perry G, Plećaš-Solarović B, Milićević Z, Bajić VP.

Neurodegener Dis. 2013;12(3):156-63. doi: 10.1159/000346114. Epub 2013 Feb 13.

PMID:
23406622
33.

Metallophilic macrophages of the rodent thymus.

Milićević NM, Milićević Ž.

Prog Histochem Cytochem. 2013 Mar;48(1):1-46. doi: 10.1016/j.proghi.2012.12.001. Epub 2013 Jan 24. Review.

PMID:
23352337
34.

Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z.

Diabet Med. 2012 Oct;29(10):1260-7. doi: 10.1111/j.1464-5491.2012.03745.x.

PMID:
22804250
35.

Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.

Jendle J, Martin SA, Milicevic Z.

Expert Opin Investig Drugs. 2012 Oct;21(10):1463-74. Epub 2012 Jul 16. Review.

PMID:
22799463
36.

Antioxidant protection against curative and palliative doses of ionizing irradiation in human blood decreases with aging.

Kasapović J, Stojiljković V, Gavrilović L, Popović N, Milićević Z.

ScientificWorldJournal. 2012;2012:982594. doi: 10.1100/2012/982594. Epub 2012 May 2.

37.

Lipopolysaccharide-induced in vivo activation of follicular dendritic cells is tumor necrosis factor receptor-1 independent.

Milićević NM, Milićević Z, Westermann J.

Anat Rec (Hoboken). 2012 Jan;295(1):87-90. doi: 10.1002/ar.21466. Epub 2011 Sep 28.

38.

Role of CCL19/21 and its possible signaling through CXCR3 in development of metallophilic macrophages in the mouse thymus.

Milićević NM, Miljković MD, Milićević Z, Labudović-Borović M, Wang X, Laan M, Peterson P, Randall TD, Westermann J.

Histochem Cell Biol. 2011 Jun;135(6):593-601. doi: 10.1007/s00418-011-0818-y. Epub 2011 May 25.

39.

Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia.

Raz I, Ceriello A, Wilson PW, Battioui C, Su EW, Kerr L, Jones CA, Milicevic Z, Jacober SJ.

Diabetes Care. 2011 Jul;34(7):1511-3. doi: 10.2337/dc10-2375. Epub 2011 May 18.

40.

Mislocalization of CDK11/PITSLRE, a regulator of the G2/M phase of the cell cycle, in Alzheimer disease.

Bajić VP, Su B, Lee HG, Kudo W, Siedlak SL, Zivković L, Spremo-Potparević B, Djelic N, Milicevic Z, Singh AK, Fahmy LM, Wang X, Smith MA, Zhu X.

Cell Mol Biol Lett. 2011 Sep;16(3):359-72. doi: 10.2478/s11658-011-0011-2. Epub 2011 Apr 3.

41.

TNF receptor-1 is required for the formation of splenic compartments during adult, but not embryonic life.

Milićević NM, Klaperski K, Nohroudi K, Milićević Ž, Bieber K, Baraniec B, Blessenohl M, Kalies K, Ware CF, Westermann J.

J Immunol. 2011 Feb 1;186(3):1486-94. doi: 10.4049/jimmunol.1000740. Epub 2010 Dec 27.

42.

Secondary hypertension due to isolated interrupted aortic arch in a 60-year-old person--one-year follow up.

Mirat J, Galić E, Corić V, Rajsman G, Vrbanić L, Razov Radas M, Milicević Z, Kondza G, Tadzić R, Vcev A.

Coll Antropol. 2010 Mar;34 Suppl 1:307-9.

PMID:
20402339
43.

How to interpret results of the HEART2D trial?

Tkác I, Milićević Z, Jermendy G.

Diabetes Res Clin Pract. 2009 Dec;86 Suppl 1:S53-6. doi: 10.1016/S0168-8227(09)70010-5.

PMID:
20115933
44.

Morphometric study of healthy jejunal and ileal mucosa in adult and aged subjects.

Trbojević-Stanković JB, Milićević NM, Milosević DP, Despotović N, Davidović M, Erceg P, Bojić B, Bojić D, Svorcan P, Protić M, Dapcević B, Miljković MD, Milićević Z.

Histol Histopathol. 2010 Feb;25(2):153-8. doi: 10.14670/HH-25.153.

PMID:
20017102
45.

Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial.

Gross JL, Nakano M, Colon-Vega G, Ortiz-Carasquillo R, Ferguson JA, Althouse S, Tobian JA, Berclaz PY, Milicevic Z.

Diabetes Technol Ther. 2009 Sep;11 Suppl 2:S27-34. doi: 10.1089/dia.2009.0037.

PMID:
19772446
46.

Efficacy and safety of AIR inhaled insulin compared to insulin lispro in patients with type 1 diabetes mellitus in a 6-month, randomized, noninferiority trial.

Comulada AL, Renard E, Nakano M, Rais N, Mao X, Webb DM, Milicevic Z.

Diabetes Technol Ther. 2009 Sep;11 Suppl 2:S17-25. doi: 10.1089/dia.2009.0041.

PMID:
19772445
47.

Ultrastructure of medullary thymic epithelial cells of autoimmune regulator (Aire)-deficient mice.

Milićević Z, Milićević NM, Laan M, Peterson P, Kisand K, Scott HS, Westermann J.

Immunol Cell Biol. 2010 Jan;88(1):50-6. doi: 10.1038/icb.2009.55. Epub 2009 Sep 1.

PMID:
19721455
48.

Stereologic analysis of tissue compartments of gunshot-injured and blunt-injured spleen.

Milićević NM, Trbojević-Stanković JB, Drachenberg CB, Milićević Z.

Pathol Oncol Res. 2010 Mar;16(1):69-73. doi: 10.1007/s12253-009-9189-2. Epub 2009 Aug 9.

PMID:
19669671
49.

Cytogenetic effects of 8-Cl-cAMP on human and animal chromosomes.

Bajic V, Stanimirovic Z, Stevanovic J, Spremo-Potparevic B, Zivkovic L, Milicevic Z.

J BUON. 2009 Jan-Mar;14(1):71-7.

50.

Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications.

Milicevic Z, Hancu N, Car N, Ivanyi T, Schwarzenhofer M, Jermendy G.

Exp Clin Endocrinol Diabetes. 2009 May;117(5):223-9. doi: 10.1055/s-0028-1128126. Epub 2009 Mar 19.

PMID:
19301232

Supplemental Content

Loading ...
Support Center